Filanesib (ARRY-520), a Selective Inhibitor of Kinesin Spindle Protein, for Patients with Relapsed/Refractory MM


Filanesib (ARRY-520), a Selective Inhibitor of Kinesin Spindle Protein, for Patients with Relapsed/Refractory MM
Slides from a presentation at ASH 2013 and transcribed comments from recent interviews with Rafael Fonseca, MD (2/14/14) and Sagar Lonial, MD (2/22/14)
Lonial S et al. Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: Results from a Phase 2 study. Proc ASH 2013;Abstract 285.

Dr Fonseca is Getz Family Professor of Cancer and Chair of the Department of Internal Medicine at the Mayo Clinic Arizona in Scottsdale, Arizona.

Dr Lonial is Professor, Vice Chair of Clinical Affairs and Director of Translational Research for the B-Cell Malignancy Program in the Department of Hematology and Medical Oncology at the Emory University School of Medicine Winship Cancer Institute in Atlanta, Georgia.